Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
PDL BioPharma Inc. ( PDLI - Analyst Report ) posted second-quarter earnings of 53 cents per share, above the year-ago figure of 39 cents and the Zacks Consensus Estimate of 49 cents. Earnings were boosted by higher revenues. Moreover, a lower share count also aided earnings in the reported quarter.
PDL BioPharma generated second-quarter 2012 revenues of $125.9 million, up 3.1%. Revenues were slightly above the guidance of $125 million announced by the company in June 2012. The Zacks Consensus Estimate was also $125 million.
Quarter in Detail
PDL BioPharma generated the entire revenues for the second quarter of 2012 from royalties. PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd.'s ( RHHBY ) Avastin and Herceptin; Roche/ Novartis’ ( NVS - Snapshot Report ) Lucentis and Xolair; and Elan Corporation/Biogen Idec’s ( ELN - Snapshot Report ) / ( BIIB - Analyst Report ) Tysabri. The company will also receive royalties on Roche’s Perjeta (pertuzumab), which was launched in the US in June 2012.
Royalty revenues of $125.9 million represented an increase of 3.1% from the year-ago period. Increased royalties on sales of Herceptin, Lucentis, Xolair and Tysabri drove second quarter 2012 royalties.
Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the US to Novartis. The payment is made in accordance with a settlement agreement, which the companies had entered into in February 2011. The second-quarter 2012 revenue is net of this payment.
General and administrative (G&A) expenses were $5.1 million in the reported quarter, up approximately 36.3% due to the company’s efforts to obtain new royalty assets, legal expenses and compensation related expenses.
On June 14, 2012, PDL BioPharma paid the second quarterly dividend of 15 cents per share.
The company is expected to provide third-quarter 2012 revenue guidance in September 2012.
Our Recommendation
We currently have a Neutral recommendation on Shire. The stock carries a Zacks #4 Rank (Sell rating) in the short run.
Read the full on RHHBY
Read the full Snapshot Report on ELN
Read the full Analyst Report on PDLI
Read the full Snapshot Report on NVS
Read the full Analyst Report on BIIB